The New England journal of medicine, 2020-01, Vol.382 (3), p.211-221
2020
Details
- Autor(en) / Beteiligte
- Titel
- Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- Ist Teil von
- The New England journal of medicine, 2020-01, Vol.382 (3), p.211-221
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- A phase 3 trial of anifrolumab, a monoclonal antibody to type I interferon receptor subunit 1, showed benefit in a composite primary end point of lupus scores. A previous phase 3 trial failed to meet its primary objective but showed an effect in secondary end points.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1912196Titel-ID: cdi_proquest_journals_2339137768
- Format
- –
- Schlagworte
- Adult, Antibodies, Monoclonal, Humanized - adverse effects, Antibodies, Monoclonal, Humanized - therapeutic use, Bronchitis, Double-Blind Method, Drug therapy, Female, Glucocorticoids, Glucocorticoids - therapeutic use, Herpes zoster, Humans, Immunoglobulins, Immunosuppressive agents, Infusions, Intravenous, Interferon, Intravenous administration, Laboratories, Lupus, Lupus Erythematosus, Systemic - drug therapy, Male, Middle Aged, Monoclonal antibodies, Patient outcomes, Receptor, Interferon alpha-beta - antagonists & inhibitors, Severity of Illness Index, Skin diseases, Statistical analysis, Systemic lupus erythematosus, Testing